Supplementary Materials: Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms
Olgica Trenchevska, Randall W. Nelson and Dobrin Nedelkov Table S1 . Serum Amyloid A (SAA) proteoforms identified using mass spectrometric immunoassay. * Native SAA proteoforms represent the full-length SAA proteins derived from SAA1 (SAA1.1 and SAA1.3) and SAA2 (SAA2.1 and SAA2.2) genes; ** Truncated SAA proteoforms originate from the native SAA proteins, but are lacking one, or more amino acids from the N-terminus in the amino acid sequence. Table S2 . Apolipoproteins C-I (apoC-I), C-II (apoC-II) and C-III (apoC-III) proteoforms identified using mass spectrometric immunoassay. * Des-A apolipoprotein C-III proteoforms correspond to the truncated apoC-III proteoforms lacking one N-temrinal Alanine (des-A) residue in the amino acid sequence; ** Apolipoprotein C-III proteoforms labeled var 4 to var 9 represent glycosylated apoC-III derivatives, which contain Fucose (Fuc) in the glycan motif. Fucosylated apoC-III have recently been identified with detailed structural studies, and can also be identified using MSIA. Figure S1 . Liner mass spectra obtained apolipoproteins C-I, C-II and C-III proteoforms in human plasma sample using MSIA with chicken-egg lysozyme as an IRS.
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